Key result
Higher serum levels of TNFR 1 and TNFR 2 were associated with increased risk of cardiovascular events and mortality (HR per SD increase for TNFR 1: 1.13; 95% CI 1.05-1.22; P=0.001).
Why the study?
Are higher serum levels of TNFR1 and TNFR2 associated with increased risk of cardiovascular events and mortality in patients with stable coronary heart disease?
RCT (n=3,977)
Are higher serum levels of TNFR1 and TNFR2 associated with increased risk of cardiovascular events and mortality in patients with stable coronary heart disease?
While elevated TNFR1 and TNFR2 levels are associated with increased cardiovascular risk in stable coronary heart disease, they offer limited utility for improving clinical risk prediction beyond established factors.
TNFR1/TNFR2 levels were associated with outcomes in stable CHD; leaves open incremental predictive value beyond standard risk factors.
Background We aimed to assess the associations and predictive powers between the soluble receptors for tumor necrosis factor (TNF)‐α (TNFR1 and TNFR2) and cardiovascular outcomes in patients with stable coronary heart disease. Methods and Results CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) is a randomized clinical trial comparing clarithromycin with placebo in patients with stable coronary heart disease. The primary outcome was a composite of nonfatal acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all‐cause mortality. Patients were followed up for 10 years; discovery sample, those assigned placebo (1204 events in n=1998); and replication sample, those assigned clarithromycin (1220 events in n=1979). We used Cox regression adjusted for C‐reactive protein level, established cardiovascular risk factors, kidney function, and cardiovascular drugs. After adjustments, higher serum levels of TNFR 1 and TNFR 2 were associated with the composite outcome in the discovery sample (hazard ratio per SD increase, 1.13; 95% confidence interval, 1.05–1.22; P =0.001 for TNFR 1; hazard ratio, 1.16; 95% confidence interval, 1.08–1.24; P <0.001 for TNFR 2). The associations were similar in the replication sample. The associations with the composite outcome were mainly driven by acute myocardial infarction, cardiovascular mortality, and noncardiovascular mortality. The addition of TNFR 1 and TNFR 2 to established cardiovascular risk factors improved prediction only modestly (<1%). Conclusions Increased concentrations of circulating TNFR 1 and TNFR 2 were associated with increased risks of cardiovascular events and mortality in patients with stable coronary heart disease. Yet, the utility of measuring TNFR 1 and TNFR 2 to improve risk prediction in these patients appears limited. Clinical Trial Registration URL: https://www.clinicaltrials.gov . Unique identifier: NCT 00121550.
No takes yet. Share an insight, caveat, or question.
Carlsson et al. (2018) conducted an RCT in Stable coronary heart disease (n=3,977). Higher serum levels of TNFR 1 and TNFR 2 vs. Lower serum levels was evaluated on Composite of nonfatal acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all-cause mortality (HR 1.13, 95% CI 1.05-1.22, p=0.001). Higher serum levels of TNFR 1 and TNFR 2 were associated with increased risk of cardiovascular events and mortality (HR per SD increase for TNFR 1: 1.13; 95% CI 1.05-1.22; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: